Table 2.
Clinical Data Lung Transplant Patients With COVID-19
| All patients n = 74 | Hospitalized n = 42 | Non-hospitalized n = 32 | p-valuea | Died n = 15 | p-valueb | |
|---|---|---|---|---|---|---|
| Symptoms, n (%) | ||||||
| Fatigue | 38 (51) | 18 (43) | 15 (47) | 0.434 | 8 (53) | 0.672 |
| Dyspnoea | 30 (41) | 21 (50) | 9 (28) | 0.047 | 5 (33) | 0.649 |
| Cough | 31 (42) | 18 (43) | 13 (41) | 0.779 | 5 (33) | 0.570 |
| Chest pain | 7 (10) | 4 (10) | 3 (9) | 0.956 | 1 (7) | 0.730 |
| Fever | 31 (42) | 19 (45) | 12 (38) | 0.448 | 5 (33) | 0.570 |
| Myalgia | 13 (18) | 4 (10) | 9 (28) | 0.042 | 2 (13) | 0.702 |
| Gastro-intestinal | 21 (28) | 14 (33) | 7 (22) | 0.250 | 7 (47) | 0.051 |
| Headache | 19 (26) | 11 (26) | 8 (25) | 0.860 | 2 (13) | 0.265 |
| Upper respiratory | 33 (45) | 15 (36) | 18 (56) | 0.094 | 4 (31) | 0.844 |
| Respiratory support | ||||||
| Ambient air | 34 (46) | 2 (5) | 32 (100) | 0 (0) | ||
| Low-flow oxygen | 20 (27) | 20 (48) | 0 (0) | 4 (27) | ||
| High-flow oxygen | 5 (7) | 5 (12) | 0 (0) | 2 (13) | ||
| IMV | 15 (20) | 15 (36) | 0 (0) | 9 (60) | ||
| Treatment COVID-19 | ||||||
| None | 31 (42) | 5 (12) | 26 (81) | 2 (13) | ||
| Corticosteroids | 42 (57) | 36 (86) | 6 (19) | 13 (87) | ||
| Hydroxychloroquine | 3 (4) | 3 (7) | 0 (0) | 1 (7) | ||
| Remdesivir | 6 (8) | 6 (14) | 0 (0) | 3 (2) | ||
| Tocilizumab | 13 (18) | 13 (31) | 0 (0) | 5 (33) | ||
| Convalescent plasma | 8 (11) | 8 (19) | 0 (0) | 2 (13) | ||
| Monoclonal antibodies | 2 (3) | 2 (5) | 0 (0) | 0 (0) | ||
| Immunosuppressive medication adjustment | ||||||
| AM discontinued/lower dose | 38 (51) | 30 (71) | 8 (25) | 10 (67) | ||
| AZA | 3 (4) | 1(2) | 2 (6) | 0 (0) | ||
| MMF | 35 (47) | 29 (69) | 6 (19) | 10 (67) | ||
| CI discontinued | 1 (1) | 1 (3) | 0 (0) | 1 (7) | ||
| CI lower trough levels | 6 (8) | 6 (14) | 0 (0) | 5 (33) | ||
| mTORi discontinued | 1 (1) | 1 (2) | 0 (0) | 1 (7) | ||
| ICU admission, n (%) | 19 (26) | 19 (45) | 0 (0) | 12 (80) | ||
| Died, n (%) | ||||||
| COVID-19 related | 13 (18) | 13 (31) | 0 (0) | 13 (87) | ||
| Other cause of death | 2 (3) | 2 (5) | 0 (0) | 2 (13) |
AM, antimetabolite; AZA, azathioprine; CI, calcineurin inhibitor; ICU, intensive care unit; IMV, invasive mechanical ventilation; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitors.
Continuous variables are expressed as median (interquartile range).
a
p-value for the difference between hospitalized patients and non-hospitalized patients.
b
p-value for the difference between survivors and non-survivors.